Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Chongkundang Holdings Corp is a prominent holding company based in South Korea. Its primary function is to manage and oversee its various subsidiary companies, which operate predominantly in the pharmaceutical and health-related sectors. As a holding entity, Chongkundang Holdings Corp provides strategic guidance and financial oversight to its subsidiaries, facilitating operational efficiency and growth. The company's influence extends into diverse industries, often focusing on innovative healthcare solutions, manufacturing of pharmaceuticals, and distribution of medical supplies. This wide-ranging involvement makes Chongkundang Holdings Corp significant in the South Korean financial market, as it aligns with the growing global demand for medical and healthcare advancements. Its role as a holding company positions it as a cornerstone for fostering innovation within its subsidiaries, at the same time impacting broader industry standards and practices.
₩38,500.00
₩50.00 (-0.13%)
Live · 10:07 AM
Operating margin is thin at 6.08%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue growth slowed to 0.1%, essentially flat. This is a business that needs a catalyst.
Net debt of ₩423.71B represents 23.0x FCF, leverage limits flexibility.
3.6x earnings, 5.7x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
₩952.66B
▲ +0.1% YoY
Net Income (TTM)
₩64.37B
▲ +34.8% YoY
Op. Margin
6.94%
▲ +2.4pp YoY
ROIC
3.49%
▲ +0.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
₩33.47B
▲ +27160.4% YoY
Op. Cash Flow (TTM)
₩107.56B
▲ +163.1% YoY
Net Debt
₩423.71B
Cash & Equiv.
₩117.10B
3Y CAGR: +1.8%
Continue Research
At a P/E of 3.6 and a price-to-free-cash-flow of 5.7, Chongkundang Holdings (001630.XKRX) trades below a two-stage DCF intrinsic value of about KRW 254,479.82 per share, so at KRW 38,500.00 the stock looks undervalued (561.0% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Chongkundang Holdings scores 61/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 5.5%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about KRW 254,479.82 per share for 001630.XKRX, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around KRW 190,859.86. At today's KRW 38,500.00, that puts the stock about 561.0% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Chongkundang Holdings scores 61 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a solid business on these measures. Recent fundamentals include a 6.9% operating margin and a 3.5% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Chongkundang Holdings pays a regular dividend of about KRW 2,099.97 per share per year (typically in quarterly installments), a yield of roughly 5.5% at the current price. That is a payout ratio of about 16.2% of earnings, so the dividend is amply covered by earnings. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For 001630.XKRX's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. 001630.XKRX currently trades below its estimated intrinsic value and scores 61/100 on quality (solid). It also yields about 5.5%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.